Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

被引：3
|
作者：
Groen, Kaz
Stege, Claudia A. M.
Nasserinejad, Kazem
de Heer, Koen
Van Kampen, Roel J. W.
Leijs, Maria B. L.
Thielen, Noortje
Westerman, Matthijs
Wu, Ka Lung
Ludwig, Inge
Issa, Djamila
Velders, Gerjo A.
Vekemans, Marie-Christiane
van de Donk, Niels W. C. J.
Timmers, Gert-Jan
Sonneveld, Pieter
Seefat, Maarten R.
Croon-de Boer, Fransien
Tick, Lidwine W.
van der Spek, Ellen
De Waal, Esther G. M.
Sohne, Maaike
Ypma, Paula F.
Nijhof, Inger S.
Klein, Saskia K.
Levin, Mark-David
Zweegman, Sonja
机构：
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152112
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
80
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with transplant -eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase Ill study (PERSEUS).
    Sonneveld, Pieter
    Broijl, Annemiek
    Gay, Francesca
    Boccadoro, Mario
    Einsele, Hermann
    Blade, Joan
    Dimopoulos, Meletios A.
    Delforge, Michel
    Spencer, Andrew
    Hajek, Roman
    Schjesvold, Fredrik
    Lonergan, Sarah
    Smith, Elena
    Carson, Robin L.
    Crist, Wendy
    Garvin, Wendy S.
    Vermeulen, Jessica
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN - PREDNISONE - BORTEZOMIB IN PATIENTS ≥75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY
    Zweegman, S.
    Levin, M. -D.
    Klein, S. K.
    de Waal, E. G.
    Eeltink, C. M.
    Ypma, P. F.
    Dijk, A. C.
    Westerman, M.
    Deenik, W.
    Tanis, B.
    Slee-Valentijn, M. S.
    Minnema, M. C.
    Visser-Wisselaar, H.
    Stege, C.
    van de Donk, N. W.
    van der Holt, B.
    Nasserinejad, K.
    Sonneveld, P.
    HAEMATOLOGICA, 2017, 102 : 112 - 113
  • [43] Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
    Salcedo, Meghan
    Lendvai, Nikoletta
    Mastey, Donna
    Schlossman, Julia
    Hultcrantz, Malin
    Korde, Neha
    Mailankody, Sham
    Lesokhin, Alexander
    Hassoun, Hani
    Smith, Eric
    Shah, Urvi
    Diab, Victoria
    Werner, Kelly
    Landau, Heather
    Lahoud, Oscar
    Drullinsky, Pamela
    Shah, Gunjan
    Chung, David
    Scordo, Michael
    Giralt, Sergio
    Landgren, Ola
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (03): : 198 - 200
  • [44] Treatment of newly diagnosed, inner-city multiple myeloma patients with zoledronate, dexamethasone, and low-dose thalidomide: A phase II trial.
    Klueppelberg, Uwe
    Smith, Eric L. P.
    Braunstein, Marc J.
    Kahn, David
    Batuman, Olcay A.
    BLOOD, 2006, 108 (11) : 371B - 371B
  • [45] Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study
    Larocca, Alessandra
    Salvini, Marco
    De Paoli, Lorenzo
    Cascavilla, Nicola
    Benevolo, Giulia
    Galli, Monica
    Montefusco, Vittorio
    di Toritto, Tommaso Caravita
    Baraldi, Anna
    Spada, Stefano
    Giuliani, Nicola
    Pautasso, Chiara
    Pulini, Stefano
    Ronconi, Sonia
    Pescosta, Norbert
    Liberati, Anna Marina
    Patriarca, Francesca
    Cellini, Claudia
    Tosi, Patrizia
    Offidani, Massimo
    Cavo, Michele
    Palumbo, Antonio
    Boccadoro, Mario
    Bringhen, Sara
    BLOOD, 2018, 132
  • [46] Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry
    Jagannath, Sundar
    Rifkin, Robert M.
    Gasparetto, Cristina J.
    Toomey, Kathleen
    Durie, Brian G. M.
    Hardin, James W.
    Terebelo, Howard R.
    Wagner, Lynne
    Narang, Mohit
    Ailawadhi, Sikander
    Omel, James L.
    Srinivasan, Shankar
    He, Mia
    Ung, Brian
    Kitali, Amani
    Flick, E. Dawn
    Agarwal, Amit
    Abonour, Rafat
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (05): : 272 - 276
  • [47] Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myelome (IFM)
    Perrot, Aurore
    Lauwers-Cances, Valerie
    Touzeau, Cyrille
    Decaux, Olivier
    Hulin, Cyrille
    Macro, Magaret
    Stoppa, Anne-Marie
    Chretien, Marie Lorraine
    Karlin, Lionel
    Mariette, Clara
    Jacquet, Caroline
    Roussel, Murielle
    Guillemot, Coralie
    Devlamynck, Laure
    Avet-Loiseau, Herve
    Moreau, Philippe
    Attal, Michel
    BLOOD, 2021, 138
  • [48] Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS
    Crusoe, Edvan De Queiroz
    Leal, Joanna
    Santos, Juliana Andrade
    de Melo Santos, Herbert Henrique
    Santos, Allan de Souza
    Lucas, Larissa Ferreira
    Almeida, Alessandro de M.
    Chaves, Marcos
    Dutra, Daniela Dourado
    Hungria, Vania T. M.
    Salvino, Marco Aurelio
    Arruda, Maria da Gloria B.
    BLOOD, 2022, 140 : 7699 - 7700
  • [49] Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma
    Leng, Siyang
    Bhutani, Divaya
    Raza, Shahzad
    Assal, Amer
    Pan, Samuel
    Hu, Jianhua
    Wei, Alexander
    Mapara, Markus
    Lentzsch, Suzanne
    BLOOD CANCER JOURNAL, 2020, 10 (02)
  • [50] Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma
    Siyang Leng
    Divaya Bhutani
    Shahzad Raza
    Amer Assal
    Samuel Pan
    Jianhua Hu
    Alexander Wei
    Markus Mapara
    Suzanne Lentzsch
    Blood Cancer Journal, 10
12345